Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4016410.17816/onco40164ArticlesСтатьиResearch ArticleMammographic screening (state of the art and perspectives)Маммографический скрининг (состояние вопроса и перспективы)KomarovaLyudmila E.КомароваЛюдмила Егоровна

Doctor of Biological Sciences, Prof.

д-р биол. наук, проф., руководитель научно-организационного отдела

orgotdel@ronc.ruN.N. Blokhin Russian Cancer Research CenterФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина»15082015204VOL 20, NO4 (2015)ТОМ 20, №4 (2015)91522072020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/40164

The paper discusses mammographic screening effectiveness in different countries. Large-scale epidemiological studies have demonstrated effectiveness of mammographic screening (early stage of diagnostic, less aggressive treatment, better cosmetic results), however benefits are still the subject to debate. The author presents different opinions concerning the real impact of screening and modern treatment methods in breast cancer mortality decrease as a result of screening.

В представленной статье обсуждаются вопросы эффективности маммографического скрининга в различных странах мира. Наряду с несомненными положительными результатами скрининга, такими как снижение смертности от рака молочной железы, обнаружение образований на ранних стадиях, дальнейшее менее агрессивное лечение, улучшенные косметические результаты, отмечаются неблагоприятные факторы. К ним относятся гипердиагностика, ложноположительные заключения, гиперлечение. Представлены различные мнения о непосредственном вкладе как маммографического скрининга, так и современных методов лечения на снижение смертности от рака молочной железы в результате скрининга.

mammography screeningbreast cancereffectivenessdecrease of breast cancer mortalityмаммографический скрининграк молочной железыгипердиагностикаложноположительные заключенияGlobocan 2008 http://globocan/iarc.frКаприн А.Д, Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2013 г. М.; 2014.Семиглазов В.Ф. Скрининг рака молочной железы. В кн.: Материалы VIII Российского онкологического конгресса. http://www.Rosoncoweb.ru/library congress/ru/08131Jorgensen K.J., Gotzche P.C. Overdiagnosis is publicly organized mammography screening: systemic review of incidence trends. Br. Med. J. 2009; 339: b2587Holving S., Thoresen S., Fretli S. The cumulative risk of falsepositive recall in the Norwegian breast cancer screening program. Cancer. 2004: 101: 1501-7.Gordon S. Screening, therapies behind drop in the Breast cancer death rates. N. Engl. J. Med. 2005; www.breast-cancer-research.com.Larry Axmaker. Breast cancer Death Rates. Decline Slowly but Steadily. http://www.cancer org/doc root/nws/contents January, 2005.Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M. et al. Effect of screening and adjuvant therapy on mortality from breast ancer. N. Engl. J. Med. 2005; 1784-92.Gotzsch P.C., Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 2009; 4: CDOO 1877.Humphrey L.L., Helfand M., Chan B.K., Woolf S.H. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Int. Med. 2002; 137(5, Pt 1): 347-60.Nyström L. ,Rutqvist L.E., Wall S. et al. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet. 1993; 341: 973-8.Nyström L., Andersson I., Bjurstam N. et al. Long-term effects of mammography screening: updated overview of the Swedish randomized trials. Lancet. 2002; 359: 909-19.Broeders M., Moss S., Nyström L. et al. Euroscreen Working Group. The impact of mammographic screening on breast cancer mortality in Europe: A review of observational studies. J. Med. Screen. 2012; 19 (Suppl. 1): 14-25.Erasmus M.C. Press Release 50 percent fewer deaths as result of population screening for breast cancer http://erasmus.nl/perskamer/archief/201113514487Lehtimaki T., Lundin M. Long term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res. 2011; 13: R 134.Li C.I, Anderson B.O., Moe R.E. Trends in incidence rates of invasive lobular and ductal carcinoma. J. A. M. A. 2003; 289 (11): 1421-4.Ma L., Fishell E. Case-Control study of factors associated with future to detect breast cancer by mammography. J. Natl. Cancer Inst. 1992; 84: 781-5.Lopez J.K., Basseti .LW. Invasive lobular carcinoma of the breast: spectrum of mammographic, US and MR imaging findings. Radiographics. 2009, 29: 165-76.Porter P.L., El-Baslawissi A.Y. et al. Breast tumor characteristics as predictors mammographic detection: comparison of interval and screen-detected cancers. J. Natl. Cancer Inst. 1999; 91(23): 2020-8.Horn P.L., Thomson W.D. Risk of contralateral breast cancer: association with histologic clinical and therapeutic factors. Cancer Epidem. Biomarkers Prev. 1999; 8: 855-61.Burrell H.C., Sibberving D.M., Wilson H.R. et al. Screening interval breast cancer mammographic features and prognosis factors. Radiology. 1996; 199: 811-7.Habel L.A., Moe R.E., Daling J.R. et al. Risk of contralateralbreast cancer in women with carcinoma in Situ of the breast. Ann. Surg. 1997; 225: 69-75.Sickles E.A. Findings of mammographic screening on only one standard projection outcomes analysis. Radiology. 1998; 208(2): 471-5.Garcia Fernandez A., Chabrera C., Garcia Font M. et al. Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012. Tumour Biol. 2014; 35(2): 1945-53.Crispo A., Barba M., D’Aintog G. et al. Molecular profiles of screen detected vs symptomatic breast cancer and their impact on survival: results from a clinical series. BMC Cancer. 2013 Jan10: 13:15 doi: 10:1186 /1471-2407-13-15Tilanus-Linthorst M., Verhoog L., Obdeign I.M. et al. A BRCA1/2 mutations, high breast density and prominent publishing margins of a tumour independently contribute to a frequent false - negative mammography. Int. J. Cancer. 2002; 102 (1): 91-5.Hauge I.H., Pederson K., Olerud H.M. et al. The risk of radiation - induced breast cancers due to biennial mammographic screening in women aged 50-69 years is minimal. Acta Radiol. 2014; 55(10): 1174-9.Lee C.I., Bensink M.E., Berry K. et al. Performance goals for an adjunct diagnostic test to reduce unnecessary biopsies after screening mammography: analysis of costs, benefits and consequences. J. Am. Coll. Radiol. 2013Dec; 10(12): 924-30.Duffy S.W., Tabar L.., Chen H.H. et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer. 2002; 95 (3): 458-69.Jonsson H., Nyström L., Tomberg S. et al. Service screening with mammography of women aged 50-69 years in Sweden: effect on mortality from breast cancer. J. Med. Screen. 2001; 8 (3): 152-60.Gotzsche P.C., Jorgensen K.J. Screening for breast cancer with mammography. Cochraine Database Syst. Rev. 2013; 6: CD 001877Jorgensen K.J, Koen J.D., Gotzsche P.C. Is mammographic screening justifiable considering, its substantial overdiagnosis rate and minor effect on mortality. Radiology. 2011; 260: 621-6.Jorgensen K.J., Zahl P.H., Gotzche P.C. Breast cancer mortality in organized mammography screening in Denmark. Br. Med. J. 2010; 340: c1241.Paap E., Verbeek A.L., Botterweek A.A. et al. Breast cancer screening halves the risk of breast cancer death: a case-referent study. Breast. 2014; 23(4): 439-44.Mook S., Van Veer L.J., Rutgers E.J. et al. Independent prognostic value of screen detection in invasive breast cancer. J. Natl. Cancer. Inst. 20114 103: 585-97.Bell R.J. Screening mammography-early detection or overdiagnosis? Contribution from Australian data. Climacteric. 2014; 17 (Suppl. 2): 66-72.Miller A.B., Baines C.J., Tot A. et al. Canadian National Breast Screening Study2. Breast cancer detection and death rates among women 50 to 59 years. Can. Med. Assoc. J. 1992; 147: 1477-88.Roman M., Skaane P., Hofvind S. The cumulative risk of falsepositive screening results across screening centres in the Norwegian Breast Cancer Screening Programme. Eur. J. Radiol. 2014; 83(9): 1639-44.Rutovist L.E. Summary of the characteristics of the Swedish trials. In: Proceedings of the Falum Conference. 1996.Maximimo Redondo, Rafael Funez et al. Detection method predicts differences in biology and survival in breast cancer patients. BMC Cancer. 2012, 12: 604.Independent UK Panel on Breast cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012; 380(9855): 1778-86.Duffy S.W., Lynge E., Jonsson H. et al. Complexities in the estimation of overdiagnosis in breast cancer screening. Br. J. Cancer. 2008; 99(7): 1176-8.Mukhtar T.K., Yeates D.R., Goldacre M.J. Breast cancer mortality trends in England and assessment of the effectiveness of mammography screening: population-based study. J. Roy. Soc. Med. 2013; 106(6): 234-42.Jorgensen K.J., Klahn A., Gotzsche P.C. et al. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross - sectional study. BMC Med. 2007; 5.12.Autier P., Boniol M., Gavin A. et al. Breast cancer mortality in neighboring European countries with difficult levels of screening but similar access to treatment: trend analysis of WHO mortality database. Br. Med. J. 343: d4411, 2011.